Exelixis (EXEL) news
Recent news
Exelixis Inc: Stifel raises target price to $51 from $47
Stifel has raised its price target for Exelixis Inc. (NASDAQ:EXEL) to $51 from $47, while maintaining a "Hold" rating on the stock. This adjustment reflects updated expectations for the company’s drug development pipeline, particularly for zanzalintinib in metastatic colorectal cancer (mCRC) and…
AInvest Wire · Aug 6, 2026Exelixis Q2 adjusted EPS USD 0.91 vs. IBES estimate USD 0.79
AInvest Wire · Aug 5, 2026Exelixis Inc: UBS raises target price to $52 from $43
UBS has raised its price target for Exelixis Inc. (NASDAQ:EXEL) to $52 from $43, while maintaining a Neutral rating on the stock. The firm cited improved expectations for the company’s pipeline and ongoing strategic developments as key factors behind the adjustment. Exelixis, currently valued at…
AInvest Wire · Jul 2, 2026Exelixis Inc: Truist Securities cuts to hold from buy; raises target price to $54 from $51
AInvest Wire · Jun 25, 2026ExGen appoints Dr. Cynthia Li to its board
ExGen has announced the appointment of Dr. Cynthia Li to its board of directors, bringing extensive experience in biotechnology, oncology, and business development to the company. Dr. Li currently serves as the leader of business and corporate development at Spotlight Therapeutics, where she…
AInvest Wire · Jun 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.